

Invitation to presentation of BICO's Year-end results 2022

BICO's year-end report for the period January to December that ended on December 31, 2022, will be published in English and Swedish on Wednesday February 22, 2023, at 07:00 am CET.

Following the release of the report, a combined presentation webcast and telephone conference with the opportunity to ask questions will be held in English at 10:00 am CET on the same day, with President & CEO Erik Gatenholm and CFO Jacob Thordenberg presenting the report.

Information about the presentation and webcast:

If you wish to participate via webcast, please use the link below.

Via the webcast you can ask written questions.

<https://ir.financialhearings.com/bico-q4-2022/register>

If you wish to participate via teleconference, please register on the link below.

After registration you will be provided phone numbers and a conference ID to access the conference.

You can ask questions verbally via the teleconference.

<https://conference.financialhearings.com/teleconference/?id=5005818>

The presentation will also be available on the company's website:

<https://bico.com/investors/financials/financial-reports-and-presentations/>

For further information, please contact:

Åsa Hillsten, Senior Advisor Investor Relations, BICO Group AB

Phone: +46 70-081 81 17

Email: ash@bico.com

The information was submitted for publication, through the agency of the contact persons set out above, on February 13, 2023, at 07:00 CET.

About BICO

BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.

The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.

With 32,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world's top 20 pharmaceutical companies, and have been cited in over 11,000 publications.

Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction the world's organ shortage and speeding up drug development to create the future of life-saving treatments.

BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com

PRESS RELEASE

13 February 2023 07:00:00 CET



Attachments

[Invitation to presentation of BICO's Year-end results 2022](#)